Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

AIDS

Volumn 14, Issue 13, 2000, Pages 1943-1948

  Larder, Brendan A ^a   Hertogs, Kurt ^b   Bloor, Stuart ^a   Van Den Eynde, Ch ^b   DeCian, Wanda ^c   Wang, Yenyun ^c   Freimuth, William W ^c   Tarpley, Gary ^c  

^a Virco UK Ltd   (United Kingdom)

^b Virco BVBA   (Belgium)

^c PFIZER INC   (United States)

Author keywords

HIV resistance; Mutations; Protease inhibitors; Tipranavir

Indexed keywords

INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CROSS RESISTANCE; DRUG SENSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION;

EID: 0034623020     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200009080-00009     Document Type: Article

References (24)

1. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy
2. Clinical significance of drug resistance in HIV-1 infection
3. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor
4. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
5. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure
6. Cross-resistance analysis of human immunodeficiency virus type I variants individually selected for resistance to five different protease inhibitors
7. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
8. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations
9. Mutations associated with HIV-1 drug resistance
10. Patterns of cross-resistance among protease inhibitors in over 1500 clinical HIV-1 isolates. Comparison of genotypic and phenotypic resistance profiles
11. Resistance to human immunodeficiency virus type 1 protease inhibitors
12. Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dlhydro-4-hydroxy-2-pyrone sulfonamide class
13. Structure-based discovery of tipranavir disodium (PNU-140690E): A potent, orally bioavailable, nonpeptidic HIV protease inhibitor
14. The calanolides, a novel HIV-inhibltory class of coumarin derivatives from the tropical rainforest tree Calophyllum lanigerum
15. Structure-based design of HIV protease inhibitors: 4-Hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors
16. Structure-based design of HIV protease inhibitors: Sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptldic inhibitors
17. Safety and efficacy of PNU-140690, a new non-peptidic HIV protease inhibitor, and HIV genotypic changes in patients in a Phase II study
18. A simple and very efficient method for generating cDNA libraries
19. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
20. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay
21. Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis
22. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing